Dixon Hubard Feinour & Brown Inc Bristol Myers Squibb CO Transaction History
Dixon Hubard Feinour & Brown Inc
- $842 Million
- Q2 2022
A detailed history of Dixon Hubard Feinour & Brown Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Dixon Hubard Feinour & Brown Inc holds 62,172 shares of BMY stock, worth $3.27 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
62,172
Previous 64,897
4.2%
Holding current value
$3.27 Million
Previous $4.74 Million
1.01%
% of portfolio
0.57%
Previous 0.47%
Shares
19 transactions
Others Institutions Holding BMY
# of Institutions
2,438Shares Held
1.51BCall Options Held
29.7MPut Options Held
32.1M-
Vanguard Group Inc Valley Forge, PA187MShares$9.82 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.35 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$4.82 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$3.93 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$3.11 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $112B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...